Kuti Baruch
Vice President, Research & Development ImmunoBrain
Over 10 years of experience in leading drug discovery and translational biology across all stages of development. Kuti joined ImmunoBrain when the company was founded, following licensing of the technology that was developed at the Weizmann Institute of Science in his Ph.D. and Postdoctoral studies at Prof. Schwartz’s laboratory. Kuti holds a M.Sc. in Medical Science from Tel-Aviv University, and a Ph.D. in Neurobiology from the Weizmann Institute of Science.
Seminars
Wednesday 2nd December 2026
Tracking the Peripheral-to-CNS Pharmacodynamic Cascade of a Novel Anti-PD-L1 Immune Checkpoint Approach in Alzheimer’s Disease
3:00 pm
- Explore a fit-for-mechanism biomarker strategy for a peripherally acting, short-lived anti-PD-L1 therapy in Alzheimer’s disease
- Examine the pharmacodynamic cascade from peripheral target engagement and transient immune activation to downstream CSF biomarker changes
- Discuss how converging biomarker evidence can strengthen biological interpretation of downstream CNS activity
